FI4426269T3 - Lipidinanopartikkelit oligonukleotidien antamiseksi - Google Patents
Lipidinanopartikkelit oligonukleotidien antamiseksiInfo
- Publication number
- FI4426269T3 FI4426269T3 FIEP22813503.4T FI22813503T FI4426269T3 FI 4426269 T3 FI4426269 T3 FI 4426269T3 FI 22813503 T FI22813503 T FI 22813503T FI 4426269 T3 FI4426269 T3 FI 4426269T3
- Authority
- FI
- Finland
- Prior art keywords
- compound according
- lnp
- compound
- independently
- lipid nanoparticle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205899 | 2021-11-02 | ||
| PCT/EP2022/080576 WO2023078946A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4426269T3 true FI4426269T3 (fi) | 2025-10-20 |
Family
ID=78500458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22813503.4T FI4426269T3 (fi) | 2021-11-02 | 2022-11-02 | Lipidinanopartikkelit oligonukleotidien antamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250073177A1 (enExample) |
| EP (2) | EP4613740A3 (enExample) |
| JP (1) | JP2024540101A (enExample) |
| KR (1) | KR20240099375A (enExample) |
| CN (1) | CN118215472A (enExample) |
| AU (1) | AU2022381685A1 (enExample) |
| CA (1) | CA3236638A1 (enExample) |
| DK (1) | DK4426269T3 (enExample) |
| ES (1) | ES3048411T3 (enExample) |
| FI (1) | FI4426269T3 (enExample) |
| IL (1) | IL312431B2 (enExample) |
| MX (1) | MX2024005110A (enExample) |
| PL (1) | PL4426269T3 (enExample) |
| PT (1) | PT4426269T (enExample) |
| WO (1) | WO2023078946A1 (enExample) |
| ZA (1) | ZA202403337B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025538515A (ja) * | 2022-11-25 | 2025-11-28 | 艾斯拓康医薬科技(北京)有限公司 | イオン化脂質及びその応用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| CN117550985B (zh) * | 2023-11-08 | 2025-02-18 | 深圳厚存纳米药业有限公司 | 一种脂质化合物及其用途 |
| AU2024381228A1 (en) | 2023-11-13 | 2026-05-28 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025140594A1 (zh) * | 2023-12-29 | 2025-07-03 | 厦门赛诺邦格生物科技股份有限公司 | 一种含有多级叔胺的不对称阳离子脂质 |
| WO2026046237A1 (zh) * | 2024-08-27 | 2026-03-05 | 北京剂泰生命科技有限公司 | 肺靶向的脂质化合物 |
| CN120943786B (zh) * | 2025-07-17 | 2026-08-04 | 深圳市艾迪贝克生物技术有限公司 | 脂质化合物、其纳米颗粒及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| CA2953341C (en) * | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20190093816A (ko) * | 2016-10-26 | 2019-08-26 | 큐어백 아게 | 지질 나노입자 mRNA 백신 |
| EP3638678B1 (en) * | 2017-06-14 | 2025-12-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 MX MX2024005110A patent/MX2024005110A/es unknown
- 2022-11-02 CN CN202280072360.5A patent/CN118215472A/zh active Pending
- 2022-11-02 JP JP2024525401A patent/JP2024540101A/ja active Pending
- 2022-11-02 US US18/705,454 patent/US20250073177A1/en active Pending
- 2022-11-02 CA CA3236638A patent/CA3236638A1/en active Pending
- 2022-11-02 EP EP25189030.7A patent/EP4613740A3/en not_active Withdrawn
- 2022-11-02 EP EP22813503.4A patent/EP4426269B1/en active Active
- 2022-11-02 PL PL22813503.4T patent/PL4426269T3/pl unknown
- 2022-11-02 PT PT228135034T patent/PT4426269T/pt unknown
- 2022-11-02 KR KR1020247018042A patent/KR20240099375A/ko active Pending
- 2022-11-02 AU AU2022381685A patent/AU2022381685A1/en active Pending
- 2022-11-02 IL IL312431A patent/IL312431B2/en unknown
- 2022-11-02 WO PCT/EP2022/080576 patent/WO2023078946A1/en not_active Ceased
- 2022-11-02 DK DK22813503.4T patent/DK4426269T3/da active
- 2022-11-02 FI FIEP22813503.4T patent/FI4426269T3/fi active
- 2022-11-02 ES ES22813503T patent/ES3048411T3/es active Active
-
2024
- 2024-04-29 ZA ZA2024/03337A patent/ZA202403337B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4426269B1 (en) | 2025-07-16 |
| IL312431A (en) | 2024-06-01 |
| KR20240099375A (ko) | 2024-06-28 |
| PT4426269T (pt) | 2025-09-03 |
| JP2024540101A (ja) | 2024-10-31 |
| MX2024005110A (es) | 2024-05-31 |
| IL312431B1 (en) | 2025-12-01 |
| DK4426269T3 (da) | 2025-10-20 |
| AU2022381685A1 (en) | 2024-05-16 |
| US20250073177A1 (en) | 2025-03-06 |
| ZA202403337B (en) | 2025-08-27 |
| EP4613740A2 (en) | 2025-09-10 |
| ES3048411T3 (en) | 2025-12-10 |
| EP4613740A3 (en) | 2025-10-29 |
| CA3236638A1 (en) | 2023-05-11 |
| EP4426269A1 (en) | 2024-09-11 |
| IL312431B2 (en) | 2026-04-01 |
| WO2023078946A1 (en) | 2023-05-11 |
| CN118215472A (zh) | 2024-06-18 |
| PL4426269T3 (pl) | 2025-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220125929A1 (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor | |
| AU2006297375C1 (en) | Oligonucleotide analogues incorporating 5-aza-cytosine therein | |
| RU2175337C2 (ru) | Полинуклеотидные композиции | |
| FI4426270T3 (fi) | Lipidi-nanopartikkelit oligonukleotidien kuljetusta varten | |
| JP2024540101A5 (enExample) | ||
| Gissot et al. | Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids | |
| KR101308591B1 (ko) | 양이온성 지질을 포함하는 음이온성 약물 전달체 및 그 제조방법 | |
| JP2024540108A5 (enExample) | ||
| JP2022505234A5 (enExample) | ||
| TW202609059A (zh) | 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2015502134A5 (enExample) | ||
| EP2626427A2 (en) | Sirna conjugate and preparation method thereof | |
| JP2024505449A5 (enExample) | ||
| HRP20160078T1 (hr) | METODE I SREDSTVA ZA UČINKOVITO PRESKAKANJE EKSONA 45 U pre-mRNA DUCHENNE MIŠIĆNE DISTROFIJE | |
| JP2017525705A5 (enExample) | ||
| AU2014300980A1 (en) | Compositions for introducing RNA into cells | |
| JP2002521423A (ja) | 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子 | |
| CN102625696A (zh) | 改进的脂质制剂 | |
| CN119072464A (zh) | 新型可电离脂质和脂质纳米颗粒以及其使用方法 | |
| IL274611B2 (en) | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | |
| JP2024502948A5 (enExample) | ||
| JP2025500860A5 (enExample) | ||
| JP2020514299A5 (enExample) | ||
| US20250325490A1 (en) | Lipid compound, lipid nanoparticle comprising same and use thereof | |
| JP2025507625A (ja) | 高濃度の液体原薬を調製する方法 |